Novartis podhaler the first choice in Europe,market share exploding.ADV over Arikace
EU here it is! " TOBI Podhaler is a new, non-nebulized formulation and delivery system of
tobramycin, a pocket-sized dry powder inhaler and offers better portability than
TOBI, which is administered using a nebulizer. This does not
include the time saved on setting up and maintaining the nebulizer and
compressor.TOBI Podhaler does not need to be stored in a refrigerator and, unlike nebulized
Pa treatments, does not require a power source to operate the delivery device."
East Hanover, NJ, March 22, 2013 –Novartis announced today that the US Food and Drug Administration (FDA) has approved TOBI® Podhaler™ (tobramycin inhalation powder) 28 mg per capsule for the management of cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa) bacteria in the lungs. Pa is the leading cause of loss of lung function in CF patients. It is not known if TOBI Podhaler is safe and effective in patients under six years of age, in those with lung function outside of a certain range, or in those whose lungs contain bacteria called Burkholderia cepacia.
The podhaler is APPROVED in the United States and sales are soaring.There are alternatives for children including some therapies showing promise to stifle the disease.The podhaler is first tier in Europe and sales are rapidly exploding and capturing market share.These are facts. Arikace has years until Europe launch and as of now is not planned for the USA.Your argument is weak because you are looking for something. Insmed competing with the podhaler will be so weak in 2 to 3 years,Insmed is having a small target population in main cities only.Have you read any reports from any of Insmeds analysts? I am missing nothing,